We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$17.5B
1-Year Est. Return
50.95%
This Fund
S&P 500
This Quarter
Est. Return
+1.5%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$21.4B
AUM Growth
-$3.07B
(-13%)
Cap. Flow
-$3.45B
Cap. Flow
% of AUM
-16.12%
Top 10 Holdings %
Top 10 Hldgs %
34%
Holding
335
New
40
Increased
37
Reduced
44
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aramark
ARMK
|
+$209M |
| 2 |
KSU
Kansas City Southern
KSU
|
+$193M |
| 3 |
Howmet Aerospace
HWM
|
+$184M |
| 4 |
MIC
Macquarie Infrastructure Holdings, LLC
MIC
|
+$172M |
| 5 |
T-Mobile US
TMUS
|
+$160M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.42B |
| 2 |
MXIM
Maxim Integrated Products
MXIM
|
+$476M |
| 3 |
Willis Towers Watson
WTW
|
+$468M |
| 4 |
WORK
Slack Technologies, Inc.
WORK
|
+$462M |
| 5 |
Aon
AON
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.56% |
| 2 | Industrials | 11.54% |
| 3 | Communication Services | 11.47% |
| 4 | Financials | 11.2% |
| 5 | Technology | 11.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Labcorp
LH
$25.9B
| $100M | 0.47% |
+414,234
| New | +$104M |
|
52
Cytokinetics
CYTK
$10.4B
| $97.7M | 0.46% |
2,732,775
-143,225
| -5% | -$4.22M |
|
|
BPMC
53
DELISTED
Blueprint Medicines
BPMC
| $97.1M | 0.45% |
944,403
-180,597
| -16% | -$16.8M |
|
|
GBIO
54
DELISTED
Generation Bio
GBIO
| $87.7M | 0.41% |
350,000
| – | – |
|
|
KRTX
55
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $85.6M | 0.4% |
700,000
+70,000
| +11% | +$8.08M |
|
56
Qiagen
QGEN
$8.72B
| $76.2M | 0.36% |
1,389,921
-721,932
| -34% | -$40.2M |
|
57
Revolution Medicines
RVMD
$44B
| $75.7M | 0.35% |
2,750,000
+250,000
| +10% | +$7.28M |
|
58
Jazz Pharmaceuticals
JAZZ
$16.7B
| $74.9M | 0.35% |
+574,907
| New | +$86.9M |
|
|
SLGC
59
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $72.2M | 0.34% |
+5,826,473
| New | +$65.7M |
|
60
Caribou Biosciences
CRBU
$164M
| $70.7M | 0.33% |
+2,963,448
| New | +$72.4M |
|
61
PG&E
PCG
$38.5B
| $70M | 0.33% |
7,292,042
| – | – |
|
|
PLYA
62
DELISTED
Playa Hotels & Resorts
PLYA
| $69.2M | 0.32% |
8,352,553
| – | – |
|
|
ATTO
63
DELISTED
Atento S.A.
ATTO
| $62.9M | 0.29% |
2,230,357
| – | – |
|
64
Alibaba
BABA
$308B
| $62.4M | 0.29% |
421,400
-255,000
| -38% | -$46.4M |
|
|
INFO
65
DELISTED
IHS Markit Ltd. Common Shares
INFO
| $60M | 0.28% |
+514,900
| New | +$60.8M |
|
|
CHNG
66
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $57.3M | 0.27% |
2,738,600
| – | – |
|
|
EXAS
67
DELISTED
Exact Sciences
EXAS
| $57M | 0.27% |
597,598
+347,598
| +139% | +$36.7M |
|
|
IMGO
68
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $53.5M | 0.25% |
+2,671,313
| New | +$57.3M |
|
69
AbbVie
ABBV
$435B
| $52M | 0.24% |
+481,848
| New | +$55.1M |
|
70
Pacific Biosciences
PACB
$370M
| $50.9M | 0.24% |
1,992,250
+1,742,250
| +697% | +$51.6M |
|
71
Arrowhead Research
ARWR
$12.4B
| $49.7M | 0.23% |
796,578
+431,578
| +118% | +$27.9M |
|
|
BRMK
72
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $48.9M | 0.23% |
4,956,174
-923,826
| -16% | -$9.6M |
|
73
Biogen
BIIB
$30.7B
| $48.4M | 0.23% |
170,859
+61,859
| +57% | +$20.3M |
|
74
CALL
Pfizer
PFE
$153B
| $43M | 0.2% |
+1,000,000
| New | +$44.3M |
|
75
Protagonist Therapeutics
PTGX
$9.44B
| $42.4M | 0.2% |
2,392,000
+62,320
| +3% | +$2.66M |
|
Similar funds
BBA
MCM
LA
CM
ASRS
PP
VMPIC
HNB
Farallon Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Farallon Capital Management held 335 positions worth $21.4B, down 13% from $24.5B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Farallon Capital Management withdrew a net $3.45B in Q3 2021, closing 34 positions and reducing 44 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $1.42B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 29% a quarter earlier, followed by Industrials and Communication Services.
Against the trend, Farallon Capital Management opened a new position in Macquarie Infrastructure Holdings, LLC worth $177M.
- Farallon Capital Management's largest Q3 2021 buy was Macquarie Infrastructure Holdings, LLC: 4,361,050 shares worth $177M.
- Farallon Capital Management added most to Aramark in Q3 2021, an estimated $209M increase.
- Farallon Capital Management's biggest Q3 2021 reduction was Willis Towers Watson, cutting an estimated $468M.
- Farallon Capital Management fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $1.42B.
- Farallon Capital Management's ten largest holdings make up 34% of its $21.4B portfolio in Q3 2021.
- Farallon Capital Management opened 40 new positions and closed 34 in Q3 2021.
- Farallon Capital Management's portfolio value fell 13% quarter-over-quarter to $21.4B.
Based on Farallon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.